pharma · Melanoma · Tumor · NKTR
Nektar Therapeutics UK
Nektar Therapeutics UK Limited
Nektar Therapeutics is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker NKTR. Primary therapeutic focus areas include Melanoma, Tumor, Renal Cell Carcinoma, Alopecia Areata, Pneum
Company details
- Status
- Public
- HQ
- 455 Mission Bay Boulevard South, San Francisco, California 94158, US
- Founded
- 1990
- Employees
- 610
- Programs
- 57
- Drugs
- 31
- Patents
- 423
Quick answer
Nektar Therapeutics is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker NKTR. Primary therapeutic focus areas include Melanoma, Tumor, Renal Cell Carcinoma, Alopecia Areata, Pneumonia. NovaPharmaNews links 57 clinical program(s), 1 drug profile(s), and 423 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (32), phase 1 (14), phase 3 (11).
Company snapshot
Nektar Therapeutics UK maintains 57 tracked programs across Melanoma, Tumor, Renal Cell Carcinoma, Alopecia Areata, Pneumonia, Advanced Cancer, Atopic Dermatitis, Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment, Ventilator Associated Pneumonia, Pneumonia, Bacterial, Locally Advanced or Metastatic Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN). Mo
- 1 approved product(s) across US/EU regulatory metadata.
- 57 active pipeline program(s) linked via ClinicalTrials.gov.
- 423 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Nektar Therapeutics UK. Not investment advice.
Recent coverage
Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context
Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context, with trial facts, status, and a clear split between active development and regulatory context. This plan is built for analysts, BD teams, and investors comparing clinical-stage autoimmune assets.
Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes
Nektar Therapeutics’ pipeline remains centered on REZPEG, with active Phase 2 programs in atopic dermatitis and alopecia areata and a completed SLE study. The company also has an amphotericin B-linked program context and recent business changes that matter for BD teams and investors.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Nektar Therapeutics UK.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Nektar Therapeutics UK.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab — Phase 2
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Nektar Therapeutics UK?
-
Is Nektar Therapeutics UK publicly traded?
-
What drugs does Nektar Therapeutics UK develop or market?
-
What are the latest developments for Nektar Therapeutics UK?
-
What therapeutic areas does Nektar Therapeutics UK focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.